Columbus Clinical Services | Miami, FL

Research site

About

Columbus Clinical Services was created in 2005 since then has provide excellent patient care in our community. Our medical center provides comprehensive medical services, clinical trials and Aesthetic Medicine by experienced professionals whose goal is caring for your medical needs at any age.

Location

110 North West 27th Avenue, Miami, Florida, United States of America

Website

https://columbusclinicalservices.net

Site insights

Top conditions

Top treatments

Bococizumab

Mirikizumab

Lansoprazole

Guselkumab

Obicetrapib

Olezarsen

Plecanatide

Vonoprazan

Cariprazine

Bromocriptine mesylate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Interested in a Study?

Verified by this site

Active trials

14 of 39 total trials

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting

Ulcerative Colitis

Drug: Guselkumab

Drug: Placebo

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting

Colitis, Ulcerative

Drug: Guselkumab Dose 2

Other: Placebo

Locations recently updated

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Placebo

Drug: Olezarsen

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (3112 Ped BPD)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting

Attention Deficit/Hyperactivity Disorder

Drug: Centanafadine Hydrochloride

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling

Severe Hypertriglyceridemia

Drug: Olezarsen

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Placebo

Drug: Enlicitide Decanoate

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Enrolling

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Drug: TQJ230

Drug: Placebo

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Active, not recruiting

Bipolar I Disorder

Schizophrenia

Drug: Cariprazine Flexible Dose

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab SAR440340